(Q36985135)

17 August 2017

1 reference

title

Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes (English)

1 reference

17 August 2017

1 reference

1 reference

Philip Raskin

1

1 reference

17 August 2017

1 January 2008

1 reference

Diabetes - Metabolism: Research and Reviews

17 August 2017

1 reference

17 August 2017

24

1 reference

17 August 2017

1

1 reference

17 August 2017

3-13

1 reference

ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations

17 August 2017

1 reference

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

21 January 2018

1 reference

Combination therapy with insulin and metformin

21 January 2018

1 reference

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

21 January 2018

1 reference

Insulin plus a Sulfonylurea Agent for Treating Type 2 Diabetes

21 January 2018

1 reference

21 January 2018

Oral Antidiabetic Agents

1 reference

7 January 2021

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.

1 reference

7 January 2021

Standards of medical care in diabetes--2007.

1 reference

7 January 2021

Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory

1 reference

7 January 2021

Addition of insulin to oral therapy in patients with type 2 diabetes

1 reference

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

7 January 2021

Metformin added to insulin therapy in poorly controlled type 2 diabetes

1 reference

7 January 2021

Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

1 reference

7 January 2021

Basic approach to managing hyperglycemia for the nonendocrinologist

1 reference

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

7 January 2021

Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

1 reference

7 January 2021

Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes

1 reference

7 January 2021

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

1 reference

7 January 2021

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

1 reference

7 January 2021

The effects of thiazolidinediones on blood pressure levels - a systematic review

1 reference

7 January 2021

Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus

1 reference

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

7 January 2021

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

1 reference

7 January 2021

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

7 January 2021

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

7 January 2021

Recent evidence of sustained benefit with exenatide in Type 2 diabetes

1 reference

7 January 2021

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

7 January 2021

Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets

1 reference

7 January 2021

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

1 reference

7 January 2021

Acarbose in the treatment of elderly patients with type 2 diabetes.

1 reference

7 January 2021

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

1 reference

7 January 2021

Effects of enzyme inducers and inhibitors on the pharmacokinetics of metformin in rats: involvement of CYP2C11, 2D1 and 3A1/2 for the metabolism of metformin

1 reference

7 January 2021

Thiazolidinediones: a new class of antidiabetic drugs

1 reference

7 January 2021

Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes

1 reference

7 January 2021

Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

1 reference

7 January 2021

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

7 January 2021

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

1 reference

7 January 2021

Faster publication isn't always better

1 reference

7 January 2021

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

1 reference

7 January 2021

Thiazolidinediones and inflammation

1 reference

7 January 2021

Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes

1 reference

7 January 2021

Thiazolidinediones and progression of renal disease in patients with diabetes

1 reference

7 January 2021

Combined thiazolidinedione-insulin therapy: should we be concerned about safety?

1 reference

7 January 2021

Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus

1 reference

7 January 2021

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

7 January 2021

Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?

1 reference

7 January 2021

Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update

1 reference

7 January 2021

Differentiating members of the thiazolidinedione class: a focus on safety

1 reference

7 January 2021

The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients

1 reference

7 January 2021

Improved glycemic control without weight gain using triple therapy in type 2 diabetes

1 reference

7 January 2021

Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients.

1 reference

7 January 2021

Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility

1 reference

7 January 2021

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.

1 reference

7 January 2021

Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis

1 reference

7 January 2021

Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.

1 reference

7 January 2021

Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial.

1 reference

7 January 2021

Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus.

1 reference

7 January 2021

Are sulfonylureas passé?

1 reference

7 January 2021

Sulfonylureas and the risk of myocardial infarction

1 reference

7 January 2021

Drug-induced hypoglycemic coma in 102 diabetic patients

1 reference

7 January 2021

Hypoglycemia-induced myocardial infarction: an unusual adverse effect of sulfonylureas

1 reference

7 January 2021

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring

1 reference

7 January 2021

Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents

1 reference

7 January 2021

Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus

1 reference

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

7 January 2021

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

1 reference

7 January 2021

Premixed insulin analogues for the treatment of diabetes mellitus

1 reference

7 January 2021

Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues

1 reference

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

7 January 2021

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs

1 reference

7 January 2021

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.783

1 reference

17 August 2017

1 reference

PubMed ID

17968971